ArticleBMC medicine2026
CD81 restricts decidual IGF2-mediated smooth muscle cell dedifferentiation during spiral artery remodeling in preeclampsia.
Article in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundPreeclampsia (PE) is a pregnancy-specific complication characterized by defective spiral artery remodeling, notably due to the abnormal retention of differentiated vascular smooth muscle cells (VSMCs). Although elevated CD81 levels in the placenta and maternal circulation contribute to this impairment, the definite mechanisms remain elusive. This study aimed to investigate how CD81 overexpression in extravillous trophoblasts (EVTs) contributes to defective VSMC dedifferentiation within uterine spiral arteries, as well as the involved molecular mechanisms.
methodsPlacental basal plates from severe preeclampsia (sPE) patients and non-PE controls were immunostained for CD81 and VSMC markers. A placental restricted CD81 overexpression mouse model was constructed to evaluate PE-like phenotype and placental pathology. Primary decidual stromal cells (DSCs) and natural killer (dNK) cells were applied to investigate how CD81-overexpressing EVTs interact with them to suppress VSMC dedifferentiation. Additionally, antagonistic and rescue experiments were conducted to identify the function of the key molecules involved.
resultsThe proportion of retained differentiated VSMCs in spiral arteries was significantly higher in sPE patients than in normal pregnancies, and was positively correlated with CD81 expression on EVTs. Similarly, pregnant mice with placental restricted CD81 overexpression exhibited PE-like phenotype and showed persistent VSMC retention in spiral arteries. In vitro, conditioned medium (CM) from DSCs pretreated with medium from CD81-overexpressing EVTs increased the expression of differentiated VSMC markers, which was associated with reduced insulin-like growth factor 2 (IGF2) levels in DSCs. Notably, exogenous IGF2 supplementation reversed this effect.
conclusionsCD81 upregulation on EVTs prevents VSMC dedifferentiation through a DSC-dependent mechanism. This study represents a pioneering effort to reveal the crucial role of interplay between EVTs, DSCs, and VSMCs in facilitating VSMC dedifferentiation, thereby enabling the completion of spiral artery remodeling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.